Business Context and Reporting Period
This Form 6-K filing by Scinai Immunotherapeutics Ltd. covers the month of November 2025. The report details significant corporate governance changes driven by recent cost-cutting measures instituted by the Company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on non-financial corporate events.
Material Changes
- Departure of Directors: Prof. Avner Rotman and Dr. Morris Laster have tendered their resignations as directors at the request of Chairman Mark Germain. These resignations are effective December 31, 2025.
- Change in Auditor: The Audit Committee has recommended appointing Ziv Haft as the new independent registered public accounting firm to reduce costs. The current firm, Kesselman & Keselman (PwC), will conclude its engagement following the next shareholder meeting.
Outlook, Risks, and Management Commentary
Management emphasizes that the reduction of the Board and the change in accounting firms are direct results of ongoing cost-cutting initiatives. The Company states there were no disagreements with the outgoing auditor, PwC, regarding accounting principles or reportable events during their tenure for the years ended December 31, 2023, and 2024. The appointment of the new auditor is subject to shareholder approval.
Investor Verification Checklist
- Confirm the effective date of the director resignations (December 31, 2025).
- Verify the outcome of the shareholder vote regarding the appointment of Ziv Haft as the new auditor.
- Review the Company's subsequent filings for details on the specific cost-cutting measures and their impact on the balance sheet.
- Check for any new disclosures regarding the composition of the Board following the departure of Prof. Rotman and Dr. Laster.